September 2019

Medical Marijuana in Community Oncology

September 17, 2019


During a presentation at the recent Community Oncology Alliance Annual Conference in Orlando, Florida, Ray Bailey, RPh, discussed the implications of medical marijuana for patients with cancer.

The Importance of Financial Counseling Services for Patients With Cancer

September 17, 2019


As the cost of treating the disease has risen, so too have the direct medical care expenses that patients pay out of pocket, as commercial insurers increasingly shift the burden of paying for treatment to patients through higher premiums, deductibles, and co-pays.

The Community Oncology Pharmacy Association: Meeting the Needs of Oncology Pharmacies

September 12, 2019


As a nonprofit focused on enhancing patient care. COPA is in a unique position to serve as a noncommercial organization dedicated to addressing community oncology pharmacy issues, all in the sole interest of patient care.

Combating Advancing Cancers With CAR T-Cell Therapy

September 08, 2019


Immunotherapy methods emerged on the oncology market as adoptive cell transfers, specifically chimeric antigen receptor (CAR) T-cell therapies, with clear benefits in hematologic malignancy treatment.

Expanding Patient Channels to Oncology Products

September 06, 2019


As new specialty products have begun to dominate the developmental pipeline, specialty pharmacy has entered the mainstream of the supply chain to the point where we can arguably refer to much of the channel as “traditional specialty.”

DAURISMO for Acute Myeloid Leukemia

September 05, 2019

Clinical Insights

On November 2018, the FDA approved Pfizer’s glasdegib (Daurismo) for the treatment of newly diagnosed acute myeloid leukemia (AML) in patients 75 years and older with comorbidities that prevent the use of intensive induction-dose chemotherapy.

ERLEADA for Prostate Cancer

September 04, 2019

Clinical Insights

On February 14, 2018, the FDA approved apalutamide (Erleada) by Janssen Biotech Inc for the treatment of nonmetastatic castration-resistant prostate cancer (NM-CRPC).